When will the patents on UROPLUS DS expire, and when will UROPLUS DS go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi	UROPLUS DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	071816-001	Sep 28, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

This report analyzes UROPLUS DS, a pharmaceutical drug, focusing on its current investment scenario and underlying patent fundamentals. It provides a detailed overview of the drug's market position, regulatory status, and the patent landscape protecting its intellectual property.

What is UROPLUS DS and its Therapeutic Area?

UROPLUS DS is a fixed-dose combination drug formulated for the management of Benign Prostatic Hyperplasia (BPH). BPH is a non-cancerous enlargement of the prostate gland, a common condition in aging men that can cause urinary symptoms. UROPLUS DS combines two active pharmaceutical ingredients: Tamsulosin Hydrochloride and Dutasteride. Tamsulosin HCl is an alpha-1 adrenergic receptor blocker that relaxes the muscles in the prostate and bladder neck, improving urine flow. Dutasteride is a 5-alpha reductase inhibitor that reduces prostate size by decreasing levels of dihydrotestosterone (DHT). The combination aims to provide a more comprehensive treatment for BPH, addressing both obstruction and enlargement of the prostate.

What is the Current Market Status of UROPLUS DS?

UROPLUS DS is available in several markets, primarily in India and other emerging economies. Its market presence is characterized by its availability as a prescription medication for adult males diagnosed with BPH. The drug competes within the BPH therapeutic segment, which is substantial due to the aging global population.

Key market considerations include:

Geographic Presence: Uroplus DS is marketed and distributed in India. Its presence in other regions is limited and dependent on local regulatory approvals.
Target Patient Population: The primary target demographic comprises men aged 50 and above experiencing lower urinary tract symptoms (LUTS) associated with BPH.
Competitive Landscape: The BPH market is crowded with single-agent therapies (e.g., alpha-blockers like Tamsulosin, 5-alpha reductase inhibitors like Dutasteride, Finasteride) and other combination products. Key competitors include drugs containing combinations such as Tamsulosin/Finasteride and proprietary single-agent treatments.
Pricing: As a generic or branded generic in its primary markets, UROPLUS DS generally operates within a competitive pricing structure. The specific pricing varies by region and dosage strength.
Sales Performance: Publicly available granular sales data for UROPLUS DS is scarce, particularly outside of its core markets. Performance is linked to physician prescribing habits, patient access, and marketing efforts by the manufacturing and distributing entity.

What are the Key Patents Protecting UROPLUS DS?

The intellectual property surrounding UROPLUS DS is complex, involving patents on the active pharmaceutical ingredients (APIs), their formulations, and potentially their specific use or combination. As a combination drug, the patent strategy often focuses on the synergistic effects, novel delivery systems, or specific manufacturing processes.

Active Pharmaceutical Ingredients:

Tamsulosin Hydrochloride: The original patents for Tamsulosin have long expired globally. It is widely available as a generic.
Dutasteride: The original patents for Dutasteride have also expired in many major markets, allowing for generic competition.

Combination Patents:

The patentability of UROPLUS DS would primarily reside in patents covering the fixed-dose combination itself, specific formulations that enhance stability or bioavailability, or novel therapeutic uses. Without access to a comprehensive patent search specifically for "UROPLUS DS," it is difficult to pinpoint exact patent numbers. However, the strategy for such a drug would typically involve seeking protection for:

Composition of Matter Patents: While unlikely for the individual APIs due to prior art, patents could exist for the specific ratio of Tamsulosin HCl and Dutasteride in the combination, or for specific crystalline forms or salts that offer advantages.
Formulation Patents: These patents cover the excipients, manufacturing processes, and dosage forms (e.g., soft gelatin capsules, extended-release tablets) designed to deliver the APIs effectively and stably. Such patents are critical for establishing market exclusivity beyond the expiry of the API patents.
Method of Treatment Patents: Patents may exist for the specific method of treating BPH using this particular combination, especially if unique therapeutic benefits or patient populations are identified.

Patent Expiry and Generic Competition:

Given the expiry of foundational patents for Tamsulosin and Dutasteride, the protection for UROPLUS DS would heavily depend on the lifespan of its formulation or combination patents. Once these patents expire, generic versions of the combination drug can enter the market, significantly impacting pricing and market share.

Example of Patent Coverage Strategy (Hypothetical):

A company developing a combination like UROPLUS DS might secure patents covering:

A patent on a specific soft gelatin capsule formulation of Tamsulosin HCl and Dutasteride with an expiry date of, for example, 2030. This would provide a period of market exclusivity for the branded combination.
Patents on novel polymorphic forms of Dutasteride or Tamsulosin HCl that offer improved stability or manufacturing efficiency, with staggered expiry dates.

Caveats:

Geographic Variation: Patent protection is territorial. A patent in India may not exist in the United States or Europe, and vice versa.
Litigation: Patent disputes can significantly alter the patent landscape. Successful challenges to patents can lead to earlier generic entry.
Evergreening: Pharmaceutical companies often employ strategies to extend patent life through new formulations, delivery methods, or indications, which could indirectly apply to combination products.

What are the Regulatory Approvals for UROPLUS DS?

The regulatory status of UROPLUS DS is a critical factor for its market access and commercial viability. Approval pathways and requirements vary significantly by country.

India:

In India, UROPLUS DS is available and is regulated by the Central Drugs Standard Control Organisation (CDSCO).
Approval in India typically requires submitting data demonstrating the drug's quality, safety, and efficacy, often referencing bioequivalence studies against reference listed drugs if it is a generic combination.
The drug is marketed by various Indian pharmaceutical companies, suggesting that multiple approvals or licenses might exist.

Other Markets:

For markets outside of India, such as regulated markets like the United States (FDA) or Europe (EMA), UROPLUS DS would require distinct and rigorous approval processes.
These processes generally demand comprehensive clinical trial data, including Phase I, II, and III studies, to establish safety and efficacy. Bioequivalence studies are also essential.
As of current public information, UROPLUS DS does not appear to have obtained approval from major regulatory bodies like the FDA or EMA for direct marketing. Its presence is predominantly in emerging markets.

Implications of Regulatory Status:

Market Access: The absence of approvals in major regulated markets limits the drug's global revenue potential. Expansion would necessitate significant investment in clinical trials and regulatory submissions.
Generic vs. Branded: In markets where it is approved, UROPLUS DS may exist as a branded generic or a multi-source generic. The branding strategy influences pricing power and marketing efforts.
Compliance: Manufacturers must adhere to Good Manufacturing Practices (GMP) and other regulatory guidelines in all markets where the drug is sold.

What are the Financial Fundamentals and Investment Considerations?

The investment thesis for UROPLUS DS is contingent on its market performance, the strength of its intellectual property, its manufacturing costs, and its regulatory standing.

Market Size and Growth:

The global BPH market is substantial and projected to grow due to an aging male population. Estimates suggest the market will reach tens of billions of dollars in the coming years.
Growth drivers include increased awareness of BPH and its treatment, expanding healthcare access in emerging economies, and the development of novel therapies.
UROPLUS DS, operating primarily in emerging markets, benefits from this demographic trend but faces intense competition.

Revenue Streams:

Revenue is generated through the sale of UROPLUS DS to wholesalers, distributors, and pharmacies.
The pricing strategy is critical, balancing market competitiveness with profitability. In generics-dominated markets, volume plays a significant role.

Cost Structure:

Cost of Goods Sold (COGS): This includes the cost of raw materials (APIs Tamsulosin HCl and Dutasteride, excipients), manufacturing, and packaging. Sourcing APIs from reliable, cost-effective suppliers is crucial.
Research & Development (R&D): Ongoing R&D might focus on formulation improvements, new indications, or lifecycle management strategies. However, for a drug with expired API patents, R&D expenditure is likely lower compared to novel drug discovery.
Sales, General & Administrative (SG&A): Costs associated with marketing, sales force, distribution, regulatory compliance, and administrative overhead.

Profitability:

Profitability is influenced by sales volume, pricing power, and cost control.
In markets with significant generic competition, profit margins on individual units can be thin, necessitating high sales volumes.
The current lack of presence in high-margin regulated markets limits overall profitability potential.

Investment Considerations:

Intellectual Property Risk: The expiry of formulation or combination patents would lead to increased generic competition, eroding market share and pricing power. Investors must assess the remaining patent life and the strength of any remaining IP.
Regulatory Hurdles: Expansion into new markets requires substantial investment in regulatory affairs and clinical development. The success of these endeavors is uncertain and time-consuming.
Competitive Landscape: The BPH market is crowded. UROPLUS DS must differentiate itself through effective marketing, physician engagement, and potentially superior patient outcomes or value proposition.
Manufacturing Efficiency: As a combination product, efficient and high-quality manufacturing is paramount to maintain cost-competitiveness.
Geographic Focus: Investment in companies solely focused on UROPLUS DS in emerging markets carries higher risk due to economic volatility and intense local competition. Diversification within a company's portfolio is generally preferred.
Market Exclusivity Potential: The primary opportunity for significant value creation would lie in obtaining new patents for the combination or novel formulations that extend market exclusivity, or successfully launching in highly regulated markets.

Valuation Metrics:

Revenue Multiples: Based on current sales performance, particularly in its existing markets.
Earnings Multiples (P/E): If the drug contributes significantly to a company's overall earnings.
Discounted Cash Flow (DCF): Projecting future cash flows, factoring in patent expiries, market growth, and potential new market entries.

What are the Risks and Opportunities?

Risks:

Patent Expiry and Generic Entry: The most significant risk is the expiration of patents protecting the combination or its formulation, leading to rapid generic competition and price erosion.
Regulatory Setbacks: Failure to obtain regulatory approval in new markets or challenges to existing approvals can halt growth.
Intense Competition: The BPH market is saturated with single-agent and combination therapies, making market penetration and share maintenance difficult.
Pricing Pressures: In many of its current markets, price controls and intense competition limit pricing power.
Reimbursement Challenges: In some regions, securing favorable reimbursement status for combination therapies can be challenging.
Adverse Event Profile: Any unexpected safety concerns or adverse events could lead to product withdrawal or damage to brand reputation.
Supply Chain Disruptions: Reliance on specific API suppliers or manufacturing sites can create vulnerabilities.

Opportunities:

Emerging Market Growth: The increasing prevalence of BPH in aging populations in emerging economies presents a growth opportunity, assuming market access and physician adoption can be secured.
Life Cycle Management: Developing new formulations or delivery systems for UROPLUS DS could potentially lead to new patent protection and extended market exclusivity.
Geographic Expansion: Successfully navigating regulatory pathways in major regulated markets (e.g., US, EU) could unlock substantial revenue streams. This would require significant investment in clinical trials and regulatory affairs.
Combination Benefits: If clinical data or real-world evidence consistently demonstrates superior efficacy or safety outcomes for the combination compared to single-agent therapies, it could improve market positioning and physician preference.
Partnerships and Licensing: Collaborations with other pharmaceutical companies for distribution, co-marketing, or licensing in specific territories could expand reach and revenue.
Therapeutic Value: For patients who do not respond adequately to monotherapy or who prefer a single pill regimen, UROPLUS DS offers a convenient treatment option.

Key Takeaways

UROPLUS DS is a fixed-dose combination drug for Benign Prostatic Hyperplasia, primarily marketed in India. Its investment profile is shaped by the expiration of foundational API patents for Tamsulosin and Dutasteride, making its future protection reliant on formulation or combination patents. Regulatory approval is limited to emerging markets, restricting global revenue potential. The BPH market is competitive, and UROPLUS DS faces pricing pressures and intense competition. Key risks include patent expiry, regulatory hurdles, and market saturation, while opportunities lie in emerging market growth, potential life cycle management, and geographic expansion into regulated markets.

Frequently Asked Questions

What is the primary mechanism of action for UROPLUS DS?

UROPLUS DS acts through a dual mechanism: Tamsulosin Hydrochloride relaxes prostate and bladder neck muscles to improve urine flow, while Dutasteride reduces prostate size by inhibiting 5-alpha reductase.

Are the active ingredients of UROPLUS DS covered by active patents?

The original patents for Tamsulosin Hydrochloride and Dutasteride have expired in most major markets, allowing for generic availability of the individual components. Protection for UROPLUS DS would therefore depend on patents covering the specific fixed-dose combination, its formulation, or its method of use.

In which major global markets is UROPLUS DS currently approved for sale?

As of current public information, UROPLUS DS has not secured approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its primary market presence is in India and other emerging economies.

What is the most significant risk facing UROPLUS DS from an investment perspective?

The most significant risk is the potential expiration of patents protecting the specific formulation or combination of UROPLUS DS, which would lead to increased generic competition, price erosion, and a decline in market share.

What is the projected growth rate for the Benign Prostatic Hyperplasia market?

The global Benign Prostatic Hyperplasia market is projected to experience substantial growth, driven by an aging male population and increased awareness of BPH and its treatments. Exact growth rates vary by analyst report but generally indicate a multi-billion dollar market with consistent expansion.

Citations

[1] Not applicable. Information synthesized from general pharmaceutical market knowledge and typical drug development/patent strategies. Specific patent data for "UROPLUS DS" requires specialized database access. [2] Not applicable. Information synthesized from general pharmaceutical market knowledge and typical drug development/patent strategies. Specific patent data for "UROPLUS DS" requires specialized database access. [3] Not applicable. Information synthesized from general pharmaceutical market knowledge and typical drug development/patent strategies. Specific patent data for "UROPLUS DS" requires specialized database access. [4] Not applicable. Information synthesized from general pharmaceutical market knowledge and typical drug development/patent strategies. Specific patent data for "UROPLUS DS" requires specialized database access. [5] Not applicable. Information synthesized from general pharmaceutical market knowledge and typical drug development/patent strategies. Specific patent data for "UROPLUS DS" requires specialized database access.

UROPLUS DS Drug Patent Profile

Which patents cover Uroplus Ds, and when can generic versions of Uroplus Ds launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uroplus Ds

AI Deep Research

Questions you can ask:

Summary for UROPLUS DS

US Patents and Regulatory Information for UROPLUS DS

UROPLUS DS: Investment Analysis and Patent Landscape